**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Marcelina Carretero, Delfina Cirelli, Paula Schwartz, Franco Faelo, Gisela Bendelman, María Agustina Marco, Elsa Nucifora, María Adela Aguirre, María Lourdes Posadas Martínez.
Submitting Author: Delfina Cirelli. Hospital Italiano de Buenos Aires. Ciudad Autónoma de Buenos Aires. Argentina.

**Main Body of the Abstract**
Background: Health-related quality of life (HRQoL) is a metric that reflects the patient's perception of their physical, mental and social well-being. It is a crucial factor to consider when assessing the impact of systemic amyloidosis on patient's lives.
Objective: To describe HRQoL in patients with systemic transthyretin amyloidosis variant type (ATTRv) within a registry of individuals with amyloidosis.
Materials & methods: Cross-sectional study (2021-2023) of ATTRv amyloidosis patients from an Amyloidosis Registry. HRQoL, assessed through the EuroQoL 5D-3L (EQ-5D-3L), was described by the proportion of patients without problems, with moderate or severe problems in each domain. Visual analog scale was presented with mean and standard deviation or median and interquartile range, depending on the distribution. Finally, the HRQoL was compared with that of the general population.
Results: Twenty-four patients were included, with a median age of 51 years, predominantly women. Paresthesias (88%), weakness, and fatigue (79%) were prevalent symptoms. Nearly all patients experienced impairment in at least one EQ-5D-3L domain. Regarding specific domains, pain or discomfort was the most common complaint. The visual analog scale revealed a median of 52. Compared to the general population, individuals with ATTRv amyloidosis demonstrated a greater compromise in HRQoL across all EQ-5D-3L domains.
Summary & Conclusion: The study reveals substantial impairment in HRQoL for ATTRv amyloidosis patients, emphasizing the need for targeted interventions. These results lay the groundwork for future research and guide clinical approaches to improve the well-being of this affected population.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Marcelina Carretero, Delfina Cirelli, Paula Schwartz, Franco Faelo, Gisela Bendelman, María Agustina Marco, Elsa Nucifora, María Adela Aguirre, María Lourdes Posadas Martínez.
Submitting Author: Delfina Cirelli. Hospital Italiano de Buenos Aires. Ciudad Autónoma de Buenos Aires. Argentina.

**Main Body of the Abstract**
**Background:** Health-related quality of life (HRQoL) is a metric that reflects the patient's perception of their physical, mental and social well-being. It is a crucial factor to consider when assessing the impact of systemic amyloidosis on patient's lives.
**Objective:** To describe HRQoL in patients with systemic transthyretin amyloidosis variant type (ATTRv) within a registry of individuals with amyloidosis.
**Materials & methods:** Cross-sectional study (2021-2023) of ATTRv amyloidosis patients from an Amyloidosis Registry. HRQoL, assessed through the EuroQoL 5D-3L (EQ-5D-3L), was described by the proportion of patients without problems, with moderate or severe problems in each domain. Visual analog scale was presented with mean and standard deviation or median and interquartile range, depending on the distribution. Finally, the HRQoL was compared with that of the general population.
**Results:** Twenty-four patients were included, with a median age of 51 years, predominantly women. Paresthesias (88%), weakness, and fatigue (79%) were prevalent symptoms. Nearly all patients experienced impairment in at least one EQ-5D-3L domain. Regarding specific domains, pain or discomfort was the most common complaint. The visual analog scale revealed a median of 52. Compared to the general population, individuals with ATTRv amyloidosis demonstrated a greater compromise in HRQoL across all EQ-5D-3L domains.
**Summary & Conclusion:** The study reveals substantial impairment in HRQoL for ATTRv amyloidosis patients, emphasizing the need for targeted interventions. These results lay the groundwork for future research and guide clinical approaches to improve the well-being of this affected population.



Health-related quality of life in hereditary transthyretin amyloidosis, a cross-sectional study PC36 (#106)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.